Risperidone versus haloperidol in children and adolescents with AD: A randomized, controlled, double-blind trial

Objective The aim of the study was to compare safety, efficacy and tolerability of risperidone with haloperidol in the treatment of Autistic Disorder (AD). Method This study was designed as a double-blind, prospective, for a 12-week period. A total of 30 subjects, between the ages of 8 and 18 with A...

Full description

Saved in:
Bibliographic Details
Published in:European child & adolescent psychiatry 2008-02, Vol.17 (1), p.1-8
Main Authors: Miral, Suha, Gencer, Ozlem, Inal-Emiroglu, F. Neslihan, Baykara, Burak, Baykara, Aysen, Dirik, Eray
Format: Article
Language:English
Subjects:
Adolescent
Alanine Transaminase - blood
Antipsychotic Agents - adverse effects
Antipsychotic Agents - therapeutic use
Autistic Disorder - diagnosis
Autistic Disorder - drug therapy
Autistic Disorder - psychology
Biological and medical sciences
Child
Child and Adolescent Psychiatry
Child Behavior Disorders - diagnosis
Child Behavior Disorders - drug therapy
Child clinical studies
Developmental disorders
Dose-Response Relationship, Drug
Double-Blind Method
Dyskinesia, Drug-Induced - etiology
Female
Humans
Infantile autism
Male
Medical sciences
Medicine
Medicine & Public Health
Neuropharmacology
Original Contribution
Outcome Assessment (Health Care)
Personality Assessment
Pharmacology. Drug treatments
Prolactin - blood
Psychiatry
Psycholeptics: tranquillizer, neuroleptic
Psychology. Psychoanalysis. Psychiatry
Psychopathology. Psychiatry
Psychopharmacology
Risperidone - adverse effects
Risperidone - therapeutic use
Citations: Items that this one cites
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:Objective The aim of the study was to compare safety, efficacy and tolerability of risperidone with haloperidol in the treatment of Autistic Disorder (AD). Method This study was designed as a double-blind, prospective, for a 12-week period. A total of 30 subjects, between the ages of 8 and 18 with AD based on DSM IV criteria, were included in the study. Behavioral Rating Scales were performed by the investigators and the parents. Safety assessment included vital signs, electrocardiogram, electroencephalogram, adverse events, laboratory tests, extrapyramidal symptoms and the side effects. Both treatments were applied in a once daily dosage regimen of 0.01–0.08 mg/kg/day. Results The reduction from baseline in Ritvo–Freeman Real Life Rating Scale (RF-RLRS), sensory motor (subscale I) and language (subscale V) scores were significant in risperidone group ( P  
ISSN:1018-8827
1435-165X
DOI:10.1007/s00787-007-0620-5